Clinical Trial Update: Assessment of Switching From Salmeterol/Fluticasone to Indacaterol/Glycopyrronium in a symtomaticCOPD Patient Cohort [Phase 4]

View source ↗

Summary

Phase 4 trial updating outcomes after switching symptomatic COPD patients from salmeterol/fluticasone to indacaterol/glycopyrronium.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Indacaterol/glycopyrronium (Indacaterol + glycopyrronium)
• Salmeterol/Fluticasone (fluticasone propionate/salmeterol)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: COPD | Phase 4 | Status: COMPLETED | Results posted: 2019-03-21